|Description||CP 544326, also known as taprenepag, is a potent and selective EP(2) receptor agonist. Its EC50 value is 2.8 nM. It is the active acid metabolite of the prodrug PF-04217329. It was successfully evaluated for its ocular hypotensive activity in a clinical study involving patients with primary open angle glaucoma.|
|Related CAS||1005549-94-9 (isopropyl)|
|Synonyms||2-(3-((N-(4-(1H-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid; CP-544326; CP544326; CP544326; Taprenepag; PF-0421732 metabolite|
|Solubility||DMSO: ＞ 31 mg/mL|
|Application||CP 544326 was successfully evaluated for its ocular hypotensive activity in a clinical study involving patients with primary open angle glaucoma.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||716.8±70.0 °C | Condition: Press: 760 Torr|
|Density||1.34±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
MK-2894 Na salt
The sodium salt form of MK-2894 that is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal an...
This active molecular is a prostaglandin receptor agonist and detailed information has not been published yet.
GW 627368X is a potent and selective competitive antagonist of the EP4 receptor with additional human TP receptor affinity (Ki values of 100 nM and 158 nM, resp...
A EP1 antagonist (pKi= 7.54) (pIC50= 8.5)
This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary dis...
CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist. It inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5. It ...
GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain.
Prostaglandin-E1 is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties. It can be used as a vasodilator agent increasing pe...
MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, a Gs protein-coupled receptor, with Ki of 0.7 nM. It plays important roles in ...
CP 544326, also known as taprenepag, is a potent and selective EP(2) receptor agonist. Its EC50 value is 2.8 nM. It is the active acid metabolite of the prodrug...
CP-533536, also called as Evatanepag, a 3-pyridyl sulfonamide compound, demonstrated excellent in vitro potency against prostaglandin E2 (PGE2) (induces local b...
PF-04217329 is a potent and selective EP2 receptor agonist on intraocular pressure in preclinical models of glaucoma. It is a prodrug of CP-544326. It is well t...
Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
Ifetroban is a selective Prostaglandin receptor and Thromboxane A2 receptor antagonist under the development of Bristol-Myers Squibb. Phase II clinical trials f...
PF-04418948 is a potent and selective prostaglandin EP₂ receptor antagonist with IC50 of 16 nM. Phase 1. PF-04418948 antagonizes the effects of butaprost and PG...
Misoprostol, a synthetic analog of natural prostaglandin E1, is an effective anti-ulcer agent and also has oxytocic properties.
Laropiprant is a potent, selective DP1 receptor antagonist (Ki=0.57 nM) used in combination with niacin to reduce blood cholesterol (LDL and VLDL).
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhe...
Grapiprant, also known as CJ-023,423, RQ-00000007 and AAT-007, is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic prop...
FR-181157 is an orally active prostacyclin mimetic that shows high potency and agonist efficacy at the IP receptor.